BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25557659)

  • 21. Treatment of systemic sclerosis.
    Steen VD
    Am J Clin Dermatol; 2001; 2(5):315-25. PubMed ID: 11721650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic sclerosis-scleroderma.
    Haustein UF
    Dermatol Online J; 2002 Jun; 8(1):3. PubMed ID: 12165213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic sclerosis sine scleroderma.
    Kucharz EJ; Kopeć-Mędrek M
    Adv Clin Exp Med; 2017 Aug; 26(5):875-880. PubMed ID: 29068586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of systemic sclerosis.
    Pope JE
    Rheum Dis Clin North Am; 1996 Nov; 22(4):893-907. PubMed ID: 8923602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon.
    Istok R; Czirják L; Lukác J; Stancíková M; Rovenský J
    Rheumatology (Oxford); 2001 Feb; 40(2):140-6. PubMed ID: 11257149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
    Jaeger VK; Wirz EG; Allanore Y; Rossbach P; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Balbir Gurman A; Tikly M; Vettori S; Damjanov N; Müller-Ladner U; Distler JH; Li M; Walker UA;
    PLoS One; 2016; 11(10):e0163894. PubMed ID: 27706206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic sclerosis: Recent insight in clinical management.
    Zanatta E; Codullo V; Avouac J; Allanore Y
    Joint Bone Spine; 2020 Jul; 87(4):293-299. PubMed ID: 31568838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raynaud's phenomenon.
    Hughes M; Herrick AL
    Best Pract Res Clin Rheumatol; 2016 Feb; 30(1):112-32. PubMed ID: 27421220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raynaud phenomenon and the vascular disease in scleroderma.
    Kahaleh MB
    Curr Opin Rheumatol; 2004 Nov; 16(6):718-22. PubMed ID: 15577610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of systemic sclerosis.
    Pope J
    Curr Opin Rheumatol; 1993 Nov; 5(6):792-801. PubMed ID: 7509616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.
    Sunderkötter C; Riemekasten G
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii33-5. PubMed ID: 16987831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Systemic sclerosis. Which therapies?].
    Bettoni L
    Minerva Med; 2001 Apr; 92(2):121-7. PubMed ID: 11323574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin and systemic sclerosis. An emerging player in pathogenesis.
    Sagonas I; Daoussis D
    Joint Bone Spine; 2022 May; 89(3):105309. PubMed ID: 34800695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hand involvement in systemic sclerosis].
    Mouthon L
    Presse Med; 2013 Dec; 42(12):1616-26. PubMed ID: 24268960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
    Arthritis Rheum; 1980 May; 23(5):581-90. PubMed ID: 7378088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of long-term left ventricular dysfunction and remodelling in systemic sclerosis: 7-year follow-up study.
    Mizuno R; Fujimoto S; Saito Y; Nakamura S
    Eur J Heart Fail; 2010 Mar; 12(3):268-75. PubMed ID: 20071354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R; Generini S; Luppi F; Pignone A; Matucci-Cerinic M
    Arthritis Rheum; 2004 Aug; 51(4):665-9. PubMed ID: 15334442
    [No Abstract]   [Full Text] [Related]  

  • 40. [How to recognize scleroderma].
    Francès C; Ayoub N; Barete S
    Rev Prat; 2002 Nov; 52(17):1884-90. PubMed ID: 12532864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.